Get the Stockscreener App
2.81
0.71%
-0.02
After Hours:
2.81
Annexon Inc stock is traded at $2.81, with a volume of 572.75K.
It is down -0.71% in the last 24 hours and down -32.61% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$2.83
Open:
$2.89
24h Volume:
572.75K
Relative Volume:
0.42
Market Cap:
$299.53M
Revenue:
-
Net Income/Loss:
$-134.24M
P/E Ratio:
-1.5876
EPS:
-1.77
Net Cash Flow:
$-121.34M
1W Performance:
-8.47%
1M Performance:
-32.61%
6M Performance:
-52.45%
1Y Performance:
-42.77%
1-Day Range:
$2.78
$2.93
1-Week Range:
$2.635
$3.17
52-Week Range:
$2.635
$8.40
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650)-822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
2.81 | 299.53M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-30-23 | Initiated | Wells Fargo | Overweight |
| May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-16-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | BTIG Research | Buy |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-26-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
Annexon executive sells shares worth $16,379 By Investing.com - Investing.com South Africa
Annexon chief medical officer sells $16,342 in common stock - Investing.com
Annexon EVP Ted Yednock sells $24,283 in stock - Investing.com
Annexon executive sells shares worth $16,379 - Investing.com
Annexon chief business officer sells $19,523 in company stock - Investing.com
Annexon EVP Ted Yednock sells $24,283 in stock By Investing.com - Investing.com South Africa
Annexon CFO Jennifer Lew sells shares worth $20,183 By Investing.com - Investing.com South Africa
Annexon CFO Jennifer Lew sells shares worth $20,183 - Investing.com
Annexon chief medical officer sells $16,342 in common stock By Investing.com - Investing.com UK
Annexon CFO Jennifer Lew Sells Shares to Cover Tax Obligations - TradingView
Annexon, Inc. (NASDAQ:ANNX) Short Interest Update - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Douglas Love Sells 5,021 Shares of Annexon, Inc. (NASDAQ:ANNX) Stock - MarketBeat
Annexon EVP sells $4,260 in stock to cover tax obligations By Investing.com - Investing.com Canada
Annexon EVP Ted Yednock sells $5,331 in stock By Investing.com - Investing.com Canada
Annexon CFO Jennifer Lew sells $5,322 in stock By Investing.com - Investing.com South Africa
Annexon EVP sells $4,260 in stock to cover tax obligations - Investing.com India
Annexon CFO Jennifer Lew sells $5,322 in stock - Investing.com India
Annexon CEO Love Douglas sells $14,811 in stock By Investing.com - Investing.com South Africa
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Employee Stock Options Alert: Annexon Awards Major Equity Package Worth $1.6M - StockTitan
Annexon stock hits 52-week low at $3.04 amid market challenges - MSN
Annexon, Inc. (NASDAQ:ANNX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Form 8-KCurrent report - br.ADVFN.com
Annexon's ANX007 Shows Significant Retinal Protection In Geographic Atrophy In Phase 2 Trial - Nasdaq
A look into Annexon Inc (ANNX)’s deeper side - SETE News
Annexon Announces Presentations Highlighting ANX007 - GlobeNewswire
Annexon Inc (NASDAQ: ANNX) Slashes -3.54%: What Could Be On The Way Going Forward? - Stocks Register
Revolutionary Eye Treatment ANX007 Preserves Vision in Geographic Atrophy Patients: Clinical Data Revealed - StockTitan
Critical Survey: Prothena (NASDAQ:PRTA) vs. Annexon (NASDAQ:ANNX) - Defense World
A stock that deserves closer examination: Annexon Inc (ANNX) - US Post News
Annexon Inc (ANNX) Shares Decline Despite Market Challenges - The News Heater
Check out these key findings about Annexon Inc (ANNX) - SETE News
Annexon Inc [ANNX] Investment Guide: What You Need to Know - Knox Daily
A year in review: Annexon Inc (ANNX)’s performance in the last year - US Post News
Market Update: Annexon Inc (ANNX) Sees Negative Movement, Closing at 3.52 - The Dwinnex
Analyzing the Impact of Earnings Reports on Annexon Inc Inc. (ANNX) Price Performance - The InvestChronicle
Annexon, Inc. (NASDAQ:ANNX) Short Interest Up 23.7% in January - MarketBeat
Annexon (NASDAQ:ANNX) and Tonix Pharmaceuticals (NASDAQ:TNXP) Head-To-Head Comparison - Defense World
What's Driving These Stocks Higher In After-hours? - RTTNews
Vanguard Group Inc's Strategic Acquisition of Annexon Inc Shares - GuruFocus.com
Annexon stock touches 52-week low at $3.85 amid market challenges - Investing.com Australia
Critical Survey: Day One Biopharmaceuticals (NASDAQ:DAWN) vs. Annexon (NASDAQ:ANNX) - Defense World
Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals - MSN
Cantor Fitzgerald Estimates Annexon FY2025 Earnings - Defense World
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Annexon Inc Stock (ANNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER |
Feb 18 '25 |
Sale |
2.97 |
5,515 |
16,380 |
83,814 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Feb 18 '25 |
Sale |
2.91 |
8,345 |
24,284 |
61,237 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Feb 18 '25 |
Sale |
2.95 |
6,618 |
19,523 |
86,579 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER |
Feb 18 '25 |
Sale |
2.92 |
6,912 |
20,183 |
77,770 |
| Love Douglas | PRESIDENT AND CEO |
Feb 13 '25 |
Sale |
2.95 |
5,021 |
14,812 |
351,554 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER |
Feb 13 '25 |
Sale |
2.98 |
1,786 |
5,322 |
84,682 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Feb 13 '25 |
Sale |
2.99 |
1,425 |
4,261 |
93,197 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Feb 13 '25 |
Sale |
2.99 |
1,783 |
5,331 |
69,582 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):